1. In Vivo
  2. >>Global Vision

Lessons From Generic Launches: About The Study

IMS Consulting Group studied 4,564 generic launches dating between July 1, 2005 and July 31, 2010, in order to gauge key criteria for success.

IMS Consulting Group studied 4,564 generic launches dating between July 1, 2005 and July 31, 2010. (See Table 1.) A product was defined by its combination of molecule, form, and manufacturer. The product strength with the greatest volume share in the second quarter of 2011, one year after the latest launch, was used for the analysis. Drugs with more than two active ingredients were excluded, as were vitamins and supplements. Forms were defined based on New Form Code classifications, but were grouped into three larger categories: “simple” oral solids, modified-release oral solids, and injectables/parenterals. Data were accessed from the IMS MIDAS database, including retail and hospital sales. (SeeAlso see "Entering The Generics Business In Mature Markets: Lessons Learned From 4,500 Launches" - In Vivo, 13 March, 2013..)

For each generic product launch, one-year volume share after launch was calculated by dividing standard units sold in the fourth...

Welcome to In Vivo

Create an account to read this article

Already a subscriber?

More from Global Vision

By The Numbers: Phase III Trials In China Skyrocket While Phase I Falls To Earth

 
• By Mainbayar Badarch

China has rapidly expanded its clinical trial footprint since 2015, driven by regulatory reforms and increased investment in pharma R&D. By 2023, it matched the US in trial volume. Oncology leads, but biologics are leading in momentum.

Navigating the GLP-1 Opportunity In China: Strategic Imperatives For Western Pharma

 
• By Jo Shorthouse

The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By Barnaby Pickering

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By Jung Won Shin

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

More from In Vivo

Enabling Precision Medicine At Scale Through Digital Innovation And AI

 
• By Cristal Thompson and Justyna Anna Lisowska

AI is reshaping clinical trials by enabling precision medicine, accelerating patient stratification, optimizing trial design, and transforming complex data into actionable insights for faster, more effective drug development.

J&J Challenges Medtronic At The Top Of Medtech Rankings

 
• By Ashley Yeo

Medtronic held its grip on first place in the 2024 global medical device and diagnostics rankings after losing it two years ago to Abbott, which is now in third place behind fast-rising, acquisitive Johnson & Johnson MedTech.

‘By Most Measures A Failure’: Ten Years On From Teva-Actavis

 
• By Dean Rudge

A decade after Teva’s $40.5bn acquisition of Actavis Generics, the deal remains a defining moment for the company. This retrospective explores Teva’s hopes, consequences, leadership shifts, and the firm’s new growth strategy under CEO Richard Francis.